Bidding results of 45 drugs including amoxicillin are released, Qilu and Huahai become the biggest winners

On the evening of November 24, 2021, the Guangdong Pharmaceutical Trade Center announced the results of the proposed selection of 45 pharmaceutical groups including Amoxicillin in Guangdong Union, involving 117 product regulations and 133 pharmaceutical companies

1.

The collection areas of Guangdong Union include Guangdong, Shanxi, Jiangxi, Henan, Hunan, Guangxi, Hainan, Guizhou, Gansu, Qinghai, Ningxia, Xinjiang, Xinjiang Production and Construction Corps, a total of 13 provinces

It is worth noting that Guangdong Union Central Procurement is divided into over-evaluated and non-over-evaluated categories in the list of purchased products

The specific classifications are as follows: 1.

According to Guangdong rules, companies need to declare two prices (P1 and P2 prices)

For purchase order A, the number of effective quotation companies≦2, P1 is the price corresponding to 60% of the pre-purchasing volume, and P2 is the price corresponding to 60% of the pre-purchasing volume; for the purchase order A, the number of valid quotation companies is ≧3 and there is in the purchase order B For companies with pre-purchasing volume, P1 is the price corresponding to 100% of the pre-purchasing volume, and P2 is the price corresponding to 100% of the pre-purchasing volume

On the whole, the outstanding feature of Guangdong Union Central Purchasing is that "products are divided into two groups AB according to whether they have been reviewed or not, three purchase lists of ABC are divided according to the market pattern, one product one price limit, step quotation P1P2, unit comparable price ≤ 0.

Judging from the bid winning results, the average price reduction rate of Guangdong Union Centralized Purchasing is about 30%, and the price reduction rates of each variety in the A/B group are very different

Most of the P1 and P2 bid prices differ only by 0% to 1%, but there are also some companies that have a large difference between P1 and P2.

In addition, the price drop of ≤2 selected companies in Group A was also relatively weak.

2.

The results of this alliance’s selection process show that among domestic companies, Qilu Pharmaceuticals (including Qilu Hainan) and Huahai Pharmaceuticals are the biggest winners.

Followed by Kelun Pharmaceutical, Hengrui, and Jingxin Pharmaceutical, with 6, 5, and 5 products winning bids respectively

In addition, a total of 8 foreign-funded companies won the bid, mainly Sanofi, Dr.
Reddy of India, Pfizer, Merck, Sino-US Shanghai Squibb, Vianex SA-Plant C, Kagamiishi Plant, Nipro Pharma Corporation, and MIKASA SEIYAKU CO.
,LTD.
KAKEGAWA FACTORY
.
details as follows:

Previous rules show that the central procurement cycle of this round of alliances does not exceed two years in principle, and the procurement agreement is signed every year during the procurement cycle
.
When the purchase agreement is renewed, the agreed purchase volume shall be converted according to the total amount of pre-purchasing in the first year of the purchase period, and in principle shall not be less than the agreed purchase volume of the selected product in the previous year
.
During the procurement cycle, if the medical institution completes the contracted purchase volume of the current year in advance, the part that exceeds the contracted purchase volume will be given priority to purchase the selected products
.

When the purchase period of the first year ends and the purchase agreement is renewed in the second year, if the actual purchase volume of the selected company exceeds the total amount of pre-purchasing in the first year of the purchase period and the second-tier quotation is not implemented, the renewed price will be taken from the company's second-tier quotation
.

In the bidding, the Guangdong Union Centralized Procurement took into account factors such as the previous selected prices, clinical reports, competition levels, and supply conditions, and formulated the highest effective declaration price based on "one product, one policy".
The lowest price, individual varieties have been lowered and raised on the basis of the past price limit.
When the quotation exceeds the highest effective declaration price and the lowest selected price in the country, the price will be regarded as an invalid quotation
.

In terms of rules, Guangdong Union’s centralized procurement has maintained the existing market structure and has little impact on leading companies.
Small companies still need to maintain a competitive situation
.
In addition, the precise price limit of one product and one policy also shows that the lowest price is no longer blindly pursued, and the price is more reasonable
.

Industry analysts pointed out that the 45 national procurement renewal bidding is beneficial to manufacturers with a high market share, mainly in Group A, because the competition is not fierce and the market is relatively stable
.
There are many types of product manufacturers in Group B, and the competition is fierce.
The price cuts that originally won the bid price were uneven, but the first and third batches of China's bids with the smallest quotation unit ≤ 0.
2 yuan basically won the bid
.

Attached: Guangdong Union Amoxicillin and other 45 pharmaceutical groups with volume purchase results (application regulations) publicity form

Follow Sina Pharmaceuticals (sinayiyao) and reply "Guangdong Union" in the backstage dialog box, and you can get the results of the planned selection of the Guangdong Union Amoxicillin and other 45 pharmaceutical groups with volume procurement, and the Guangdong Union Amoxicillin and other 45 pharmaceutical groups with the volume procurement documents
.

Article reference:

1.
"Pharmaceutical Time" announced the results of the continued bidding of Guangdong 21+1 Alliance: "Cry, laugh, and howl!" !

2.
Geng Hongwu: The four most typical Beijing, Shanghai, Guanghan and Guanghan models for the “renewal of bids” for centralized drug purchases organized by the state